Ardelyx and Knight collaborate to bring Tenapanor to patients in Canada
Ardelyx announced a license agreement with Knight Therapeutics that provides Knight with exclusive rights to commercialize tenapanor in Canada. Tenapanor is Ardelyx's oral, first-in-class small molecule treatment that has completed Phase 3 development for irritable bowel syndrome with constipation. March 19, 2018